Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · IEX Real-Time Price · USD
0.370
+0.005 (1.37%)
Apr 26, 2024, 2:19 PM EDT - Market open
Kazia Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Kazia Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for KZIA.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 | Mar '23 | Apr '23 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $2 | Hold → Strong Buy | Upgrades | $2 | +440.83% | Apr 11, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 2, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 2, 2022 |
| Maxim Group | Maxim Group | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Oct 14, 2021 |
Financial Forecast
Revenue This Year
22.50M
from 23.00K
Increased by 97,726.09%
Revenue Next Year
22.50M
from 22.50M
EPS This Year
0.01
from -1.12
EPS Next Year
0.01
from 0.01
Increased by 27.27%
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 23.2M | 23.2M |
| Avg | 22.5M | 22.5M |
| Low | 21.6M | 21.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 100,604.3% | 2.9% |
| Avg | 97,726.1% | - |
| Low | 93,891.3% | -3.9% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | 0.01 | 0.01 |
| Avg | 0.01 | 0.01 |
| Low | 0.01 | 0.01 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | 31.0% |
| Avg | - | 27.3% |
| Low | - | 22.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.